Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRON NASDAQ:INZY NASDAQ:JBIO NASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.70+1.9%$2.70$1.87▼$3.43$988.54M0.891.11 million shs743,749 shsINZYInozyme Pharma$4.00$3.99$0.93▼$4.00$258.25M2.272.79 million shsN/AJBIOJade Biosciences$21.86+12.4%$21.12$6.67▼$28.00$960.05M1.441.47 million shs1.39 million shsSPRYARS Pharmaceuticals$10.28+3.0%$8.65$6.66▼$18.90$991.05M0.941.41 million shs1.30 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+1.89%+3.85%-1.46%+3.05%+44.39%INZYInozyme Pharma0.00%0.00%0.00%0.00%+0.25%JBIOJade Biosciences+12.39%+40.76%-1.58%+56.70%+121.48%SPRYARS Pharmaceuticals+3.01%+5.98%+29.47%+30.13%-37.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.70+1.9%$2.70$1.87▼$3.43$988.54M0.891.11 million shs743,749 shsINZYInozyme Pharma$4.00$3.99$0.93▼$4.00$258.25M2.272.79 million shsN/AJBIOJade Biosciences$21.86+12.4%$21.12$6.67▼$28.00$960.05M1.441.47 million shs1.39 million shsSPRYARS Pharmaceuticals$10.28+3.0%$8.65$6.66▼$18.90$991.05M0.941.41 million shs1.30 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+1.89%+3.85%-1.46%+3.05%+44.39%INZYInozyme Pharma0.00%0.00%0.00%0.00%+0.25%JBIOJade Biosciences+12.39%+40.76%-1.58%+56.70%+121.48%SPRYARS Pharmaceuticals+3.01%+5.98%+29.47%+30.13%-37.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 2.20Hold$2.30-14.81% DownsideINZYInozyme Pharma 0.00N/AN/AN/AJBIOJade Biosciences 2.90Moderate Buy$47.13115.58% UpsideSPRYARS Pharmaceuticals 2.50Moderate Buy$28.60178.21% UpsideCurrent Analyst Ratings BreakdownLatest INZY, SPRY, CRON, and JBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026JBIOJade Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)6/15/2026JBIOJade Biosciences UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.006/15/2026JBIOJade Biosciences UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.006/2/2026JBIOJade Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$55.006/2/2026JBIOJade Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.006/2/2026JBIOJade Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $45.006/1/2026JBIOJade Biosciences Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/1/2026JBIOJade Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)6/1/2026SPRYARS Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/1/2026JBIOJade Biosciences BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$39.00 ➝ $74.006/1/2026JBIOJade Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $55.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$146.59M6.87$0.01 per share211.38$3.00 per share0.90INZYInozyme PharmaN/AN/AN/AN/A$0.90 per shareN/AJBIOJade BiosciencesN/AN/AN/AN/A$6.74 per shareN/ASPRYARS Pharmaceuticals$84.28M12.11N/AN/A$1.16 per share8.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group-$9.45M$0.01270.27N/AN/A-1.14%-1.26%-1.20%8/6/2026 (Estimated)INZYInozyme Pharma-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%N/AJBIOJade Biosciences-$127.41M-$2.02N/AN/AN/AN/A-51.34%-47.32%N/ASPRYARS Pharmaceuticals-$171.30M-$2.01N/AN/AN/A-200.00%-153.61%-60.85%8/12/2026 (Estimated)Latest INZY, SPRY, CRON, and JBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026SPRYARS Pharmaceuticals-$0.53-$0.61-$0.08-$0.61$22.20 million$22.68 million5/11/2026Q1 2026CRONCronos Group$0.01$0.01N/A$0.04$42.20 million$58.97 million5/7/2026Q1 2026JBIOJade Biosciences-$0.52-$0.57-$0.05-$0.57N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/AINZYInozyme PharmaN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A21.8720.73INZYInozyme Pharma0.652.192.19JBIOJade BiosciencesN/A14.2914.29SPRYARS Pharmaceuticals2.794.944.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%INZYInozyme Pharma88.30%JBIOJade BiosciencesN/ASPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipCRONCronos Group7.80%INZYInozyme Pharma12.18%JBIOJade Biosciences23.06%SPRYARS Pharmaceuticals33.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450373.03 million343.94 millionOptionableINZYInozyme Pharma5064.56 million56.70 millionOptionableJBIOJade Biosciences2049.36 million37.98 millionN/ASPRYARS Pharmaceuticals9099.30 million65.74 millionOptionableINZY, SPRY, CRON, and JBIO HeadlinesRecent News About These CompaniesARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 23 at 4:18 AM | americanbankingnews.comCreek Drive Management Group LLC Makes New Investment in ARS Pharmaceuticals, Inc. $SPRYJune 21 at 6:31 AM | marketbeat.comEversept Partners LP Cuts Stake in ARS Pharmaceuticals, Inc. $SPRYJune 18, 2026 | marketbeat.comGeneral American Investors Co. Inc. Takes $6.52 Million Position in ARS Pharmaceuticals, Inc. $SPRYJune 14, 2026 | marketbeat.comInsider Selling: ARS Pharmaceuticals (NASDAQ:SPRY) Insider Sells 3,355 Shares of StockJune 13, 2026 | insidertrades.comHow The Evolving Story For ARS Pharmaceuticals (SPRY) Could Shape Future ValuationJune 9, 2026 | finance.yahoo.comDrew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe AllergiesJune 4, 2026 | finance.yahoo.comWhy ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Up 5.30%May 20, 2026 | aaii.comAARS Pharmaceuticals: Still A Buy As Neffy Access ImprovesMay 20, 2026 | seekingalpha.comArs Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access programMay 16, 2026 | seekingalpha.comARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...May 16, 2026 | finance.yahoo.comARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call TranscriptMay 15, 2026 | seekingalpha.comARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue EstimatesMay 15, 2026 | zacks.comARS Pharmaceuticals Reports Q1 2026 Financial Results Highlighting $22.7 Million in Revenue and Progress on neffy® CommercializationMay 15, 2026 | quiverquant.comQARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate UpdateMay 15, 2026 | globenewswire.comARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsMay 15, 2026 | benzinga.comARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsMay 15, 2026 | benzinga.comARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as PresidentMay 13, 2026 | globenewswire.comARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comEarnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to DeclineMay 6, 2026 | zacks.comHow The ARS Pharmaceuticals (SPRY) Narrative Is Shifting With Fresh Analyst Models And ApprovalsMay 2, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20263 Stocks Rallying on Micron's Price Boost: Substance or Hype?By Dan Schmidt | May 28, 2026Micron’s $1 Trillion Memory Melt-UpBy Jeffrey Neal Johnson | May 27, 2026Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?By Jessica Mitacek | June 1, 2026If the Market Rally Stalls, This ETF Can Insulate PortfoliosBy Jessica Mitacek | May 28, 2026INZY, SPRY, CRON, and JBIO Company DescriptionsCronos Group NASDAQ:CRON$2.70 +0.05 (+1.89%) Closing price 06/23/2026 03:58 PM EasternExtended Trading$2.70 0.00 (0.00%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Inozyme Pharma NASDAQ:INZYInozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Jade Biosciences NASDAQ:JBIO$21.86 +2.41 (+12.39%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$22.13 +0.27 (+1.24%) As of 08:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.ARS Pharmaceuticals NASDAQ:SPRY$10.28 +0.30 (+3.01%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$10.19 -0.09 (-0.88%) As of 08:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning Why nVent Could Be a Long-Term AI Infrastructure Winner These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
